The MYG1 Knockout SK-OV-3 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed for the disruption of the MYG1 gene in the human SK-OV-3 ovarian cancer cell line. This polyclonal population comprises a heterogeneous mixture of cells with targeted gene modifications, providing a robust loss-of-function model without reliance on single-cell clonal isolation. The CRISPR/Cas9-mediated gene disruption enables researchers to investigate MYG1-dependent phenotypes in a genetically defined background, facilitating studies on gene function and signaling pathways relevant to ovarian cancer and other malignancies.
The host SK-OV-3 cell line is an epithelial ovarian adenocarcinoma model originally derived from a patient with serous cystadenocarcinoma. These cells harbor a well-characterized TP53 mutation, which contributes to their tumorigenic properties, and exhibit resistance to cisplatin, a common chemotherapeutic agent. This genetic background makes SK-OV-3 particularly valuable for studying drug resistance mechanisms and tumor cell survival. The introduction of MYG1 knockout into this clinically relevant model allows for the interrogation of molecular interactions that govern ovarian cancer progression under therapeutic pressure.
MYG1 (Melanocyte-specific gene 1) is a protein implicated in cell proliferation, survival, and differentiation, with proposed roles in mitochondrial function and RNA metabolism. Although its full regulatory network remains under investigation, MYG1 is thought to participate in key signaling cascades such as PI3K/AKT/mTOR and MAPK/ERK pathways. It potentially interacts with mitochondrial proteins and developmentally regulated GTP-binding protein 1 (DRG1), and influences downstream effectors including cell cycle regulators (Cyclins, CDKs) and anti-apoptotic factors like BCL2. Mechanistically, MYG1 disruption is expected to impair cell cycle progression and promote apoptosis, in part through reduced AKT and ERK activity, leading to dysregulation of p53, Caspase-3, and BCL2 family members. These molecular connections underscore the gene??s integrative role in balancing growth signals and cell death.
In the context of SK-OV-3 cells, MYG1 knockout provides a powerful tool to dissect ovarian cancer biology, especially given the line??s TP53 mutation and cisplatin resistance. Loss of MYG1 may exacerbate vulnerabilities in mitochondrial respiration or sensitize cells to apoptotic triggers, offering insights into synthetic lethal interactions. The polyclonal format minimizes artifacts associated with clonal selection and more closely resembles the genetic heterogeneity found in tumors, making it suitable for preclinical drug target validation and signaling pathway dissection. Researchers can assess how MYG1 loss influences key phenotypic traits such as proliferation, migration, and drug response in an ovarian cancer setting.
Typical research applications include functional genomics studies, mitochondrial function analyses, and signal transduction experiments focused on PI3K/AKT/mTOR and MAPK/ERK axes. Experimental workflows may employ Western blotting and RT-qPCR to verify MYG1 disruption and downstream protein changes, MTT or BrdU assays for proliferation, flow cytometry with Annexin V staining for apoptosis, cell cycle profiling, Boyden chamber migration assays, and colony formation tests. Moreover, mitochondrial activity assays and drug sensitivity screens can be performed to evaluate metabolic shifts and chemoresistance. For additional technical details or support, researchers are encouraged to contact Ascent Research.
